40 results
8-K
EX-99.1
PRCT
Procept BioRobotics Corp
3 May 24
Regulation FD Disclosure
8:57am
between safety & efficacy Surgeon skill can vary widely Treatment options depend on prostate size Patients forced to make tradeoff between safety … Research PRCT001 Objective Evaluate safety & efficacy of Aquablation therapy for patients with BPH & localized prostate cancer. Step 1 Step 2
8-K
EX-9.01
PRCT
Procept BioRobotics Corp
1 May 24
Results of Operations and Financial Condition
7:23am
of this press release.
Important Safety Information
All surgical treatments have inherent and associated side effects. For a list of potential side effects … visit https://aquablation.com/safety-information/
Investor Contact:
Matt Bacso
VP, Investor Relations and Business Operations
m.bacso@procept
8-K
EX-9.01
0zklq jn10trdpk9
27 Feb 24
Results of Operations and Financial Condition
4:07pm
8-K
EX-99.1
tyj8ahbs mcgfer84
1 Nov 23
PROCEPT BioRobotics® Reports Third Quarter 2023 Financial Results and Increases 2023 Revenue Guidance
4:10pm
424B5
57437gof7gj m4xu
3 Aug 23
Prospectus supplement for primary offering
4:01pm
424B5
6p1m3x5s9gu
1 Aug 23
Prospectus supplement for primary offering
4:08pm
S-3ASR
EX-25.1
1uk3kg1
1 Aug 23
Automatic shelf registration
4:01pm
8-K
EX-99.1
a3u3q64o0
27 Jul 23
PROCEPT BioRobotics® Reports Second Quarter 2023 Financial Results and Increases 2023 Revenue Guidance
7:09am
8-K
EX-99.1
cqd68po
28 Apr 23
Regulation FD Disclosure
8:30am
8-K
EX-99.1
iip9y4ukg7xj4l
27 Apr 23
PROCEPT BioRobotics Reports First Quarter 2023 Financial Results and Increases 2023 Revenue Guidance
7:02am
8-K
EX-99.1
gna0h7
3 Nov 22
PROCEPT BioRobotics Reports Third Quarter 2022 Financial Results and Increases 2022 Revenue Guidance
4:10pm